{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T17:02:09Z","timestamp":1786122129204,"version":"build-2736575974"},"reference-count":28,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: During the 2016\u20132022 period, tyrosine kinase inhibitor (TKI) monotherapy was the standard first-line option at our center before combination protocols became available. This study evaluates patients experiencing initial TKI failure who subsequently received second- or later-line nivolumab. Because clinical practice lacks low-cost, accessible tools to prognosticate outcomes in this setting, we evaluated whether baseline psoas muscle index (PMI), early on-treatment C-reactive protein (CRP) kinetics, and a specific panel of blood-derived inflammatory\/nutritional ratios offer reliable prognostic value. Materials and methods: We retrospectively reviewed data from 49 consecutive mRCC patients who progressed on a TKI and received second- or later-line nivolumab monotherapy. Primary endpoints were overall survival (OS; N = 49) and time-to-treatment failure (TTF; N = 48). We utilized Kaplan\u2013Meier and Cox regression models for analysis. Benjamini\u2013Hochberg false discovery rate (FDR) correction (q &lt; 0.05) controlled false positive inflation across two separate testing frameworks: seven log-rank assessments for TTF and the core Cox models. Adjusted models accounted for clinical covariates including International Metastatic RCC Database Consortium (IMDC) risk category, Eastern Cooperative Oncology Group performance status (ECOG PS), and de novo metastatic presentation. We calculated the intraclass correlation coefficient (ICC) to evaluate measurement reproducibility. Results: Median follow-up reached 48.4 months (reverse Kaplan\u2013Meier; maximum: 87.8 months), with a cohort-wide median OS of 13.9 months (IQR: 5.8\u201336.2). A low baseline C-reactive protein-to-albumin ratio (CAR) mapped to a distinct survival benefit, showing a median OS of 32.6 months versus 5.8 months in the high-CAR group (log-rank p &lt; 0.001; BH q = 0.003). In adjusted multivariable Cox hazards modeling, both CAR (HR: 1.029; p = 0.002) and the prognostic nutritional index (PNI; HR: 0.893; p &lt; 0.001) maintained independent prognostic significance. When evaluating the 43 patients with complete 3-month CRP records, we found a significantly higher objective response rate (ORR) in those at or below the cohort-median ratio threshold of 1.16 compared to patients above it (54.5% vs. 23.8%; p = 0.039). The overall ITT population registered an ORR of 36.7% (18\/49). Conclusions: Low pretreatment CAR and elevated PNI identify mRCC patients showing improved survival profiles in this post-TKI nivolumab subgroup. Additionally, an elevated 3-month CRP ratio correlates with compromised objective response rates and a trend toward shorter TTF, though the TTF endpoint did not clear strict FDR parameters (BH q = 0.098). These retrospective, single-center data serve strictly for signal generation and require independent prospective multi-institutional confirmation before translating to oncology practice.<\/jats:p>","DOI":"10.3390\/medicina62081520","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T08:01:36Z","timestamp":1786089696000},"page":"1520","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Integrated Inflammatory and Nutritional Biomarkers in Metastatic Renal Cell Carcinoma Treated with Second- or Later-Line Nivolumab: A Retrospective Cohort Study"],"prefix":"10.3390","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0544-6047","authenticated-orcid":false,"given":"Muzaffer","family":"U\u011frakl\u0131","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Faculty of Medicine, Necmettin Erbakan University, Konya 42090, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00dclk\u00fc","family":"Kerimo\u011flu","sequence":"additional","affiliation":[{"name":"Department of Radiology, Faculty of Medicine, Necmettin Erbakan University, Konya 42090, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3085-7964","authenticated-orcid":false,"given":"Mehmet Zahid","family":"Ko\u00e7ak","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Faculty of Medicine, Necmettin Erbakan University, Konya 42090, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9614-0651","authenticated-orcid":false,"given":"Talat","family":"Aykut","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Faculty of Medicine, Necmettin Erbakan University, Konya 42090, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4629-6815","authenticated-orcid":false,"given":"Dilek","family":"\u00c7a\u011flayan","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Faculty of Medicine, Necmettin Erbakan University, Konya 42090, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melek","family":"Karakurt Ery\u0131lmaz","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Faculty of Medicine, Necmettin Erbakan University, Konya 42090, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4632-9501","authenticated-orcid":false,"given":"Murat","family":"Araz","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Faculty of Medicine, Necmettin Erbakan University, Konya 42090, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2335-3354","authenticated-orcid":false,"given":"Mehmet","family":"Arta\u00e7","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Faculty of Medicine, Necmettin Erbakan University, Konya 42090, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,7]]},"reference":[{"key":"ref_1","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1470-2045(12)70559-4","article-title":"External validation and comparison with other models of International Metastatic Renal-Cell Carcinoma Consortium prognostic model: A population-based study","volume":"14","author":"Heng","year":"2013","journal-title":"Lancet Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab vs. everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/ageing\/afy169","article-title":"Sarcopenia: Revised European consensus definition and diagnosis","volume":"48","author":"Bahat","year":"2019","journal-title":"Age Ageing"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1038\/s41598-020-58498-2","article-title":"Weight of skeletal muscle mass and muscle density in cancer patients treated with PD-1\/PD-L1 checkpoint inhibitors: A multicenter real-life study","volume":"10","author":"Cortellini","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"10732748241302248","DOI":"10.1177\/10732748241302248","article-title":"Factors Influencing Immunotherapy Outcomes in Cancer: Sarcopenia and Systemic Inflammation","volume":"31","author":"Ucgul","year":"2024","journal-title":"Cancer Control"},{"key":"ref_8","first-page":"100153","article-title":"Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: The development of a novel prognostic score (Meet-URO 15 study)","volume":"6","author":"Rebuzzi","year":"2021","journal-title":"ESMO Open"},{"key":"ref_9","first-page":"653","article-title":"Systemic inflammatory markers predicting the overall survival of the patients using tyrosine kinase inhibitors in first-line treatment of metastatic renal cell carcinoma","volume":"33","author":"Korkmaz","year":"2023","journal-title":"J. Coll. Physicians Surg. Pak."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"415","DOI":"10.4111\/icu.20220028","article-title":"Association between sarcopenia based on psoas muscle index and the response to nivolumab in metastatic renal cell carcinoma: A retrospective study","volume":"63","author":"Ueki","year":"2022","journal-title":"Investig. Clin. Urol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/jamaoncol.2017.4771","article-title":"Association of the lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced non\u2013small cell lung cancer","volume":"4","author":"Mezquita","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Sz\u00e9les, \u00c1., Kubik, A., V\u00e1ncsa, S., Gr\u00fcnwald, V., Hadaschik, B., \u00c1cs, N., Hegyi, P., Nyir\u00e1dy, P., and Szarvas, T. (2025). Prognostic and predictive value of pre-treatment blood-based inflammatory biomarkers in patients with urothelial carcinoma treated with immune checkpoint inhibitors: A systematic review and meta-analysis. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1554048"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s10147-019-01528-5","article-title":"C-reactive protein and the neutrophil-to-lymphocyte ratio are prognostic biomarkers in metastatic renal cell carcinoma patients treated with nivolumab","volume":"25","author":"Suzuki","year":"2020","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Ueda, K., Ogasawara, N., Ito, N., Ohnishi, S., Suekane, H., Kurose, H., Hiroshige, T., Chikui, K., Uemura, K., and Nishihara, K. (2023). Prognostic value of absolute lymphocyte count in patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab. J. Clin. Med., 12.","DOI":"10.3390\/jcm12062417"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Yano, Y., Ohno, T., Komura, K., Fukuokaya, W., Uchimoto, T., Adachi, T., Hirasawa, Y., Hashimoto, T., Yoshizawa, A., and Yamazaki, S. (2022). Serum C-reactive protein level predicts overall survival for clear cell and non-clear cell renal cell carcinoma treated with ipilimumab plus nivolumab. Cancers, 14.","DOI":"10.3390\/cancers14225659"},{"key":"ref_16","unstructured":"National Cancer Institute (2026, May 15). Common Terminology Criteria for Adverse Events (CTCAE) v.5.0, Available online: https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1159\/000520833","article-title":"Body mass index, sarcopenia, and their variations in predicting outcomes for patients treated with nivolumab for metastatic renal cell carcinoma","volume":"100","author":"Herrmann","year":"2022","journal-title":"Oncology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"624","DOI":"10.2478\/raon-2025-0065","article-title":"Baseline and dynamic changes in skeletal muscle mass as predictive biomarkers in patients with metastatic renal cell carcinoma treated with nivolumab","volume":"59","author":"Ozkan","year":"2025","journal-title":"Radiol. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: RECIST guideline revised (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Guven, D.C., Sahin, T.K., Erul, E., Rizzo, A., Ricci, A.D., Aksoy, S., and Yalcin, S. (2022). The association between albumin levels and survival in patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis. Front. Mol. Biosci., 9.","DOI":"10.3389\/fmolb.2022.1039121"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"13934","DOI":"10.18632\/oncotarget.24172","article-title":"Clinicopathologic and prognostic significance of C-reactive protein\/albumin ratio in patients with solid tumors: An updated systematic review and meta-analysis","volume":"9","author":"Wu","year":"2018","journal-title":"Oncotarget"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.urolonc.2021.05.028","article-title":"Prognostic nutritional index and prognosis in renal cell carcinoma: A systematic review and meta-analysis","volume":"39","author":"Kim","year":"2021","journal-title":"Urol. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"812.e1","DOI":"10.1016\/j.urolonc.2019.04.002","article-title":"C-reactive protein-albumin ratio as a prognostic factor in renal cell carcinoma\u2014A data from multi-institutional study in Japan","volume":"37","author":"Tsujino","year":"2019","journal-title":"Urol. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e004316","DOI":"10.1136\/jitc-2021-004316","article-title":"Biomarker analysis from CheckMate 214: Nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma","volume":"10","author":"Motzer","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2618431","DOI":"10.1080\/07853890.2026.2618431","article-title":"Elevated C-reactive protein to albumin ratio is a promising predictive biomarker for prognosis in patients with renal cell carcinoma","volume":"58","author":"Xu","year":"2026","journal-title":"Ann. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1002\/jcsm.12755","article-title":"Predictive impact of sarcopenia in solid cancers treated with immune checkpoint inhibitors: A meta-analysis","volume":"12","author":"Takenaka","year":"2021","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Li, S., Wang, T., Tong, G., Li, X., You, D., and Cong, M. (2022). Prognostic impact of sarcopenia on clinical outcomes in malignancies treated with immune checkpoint inhibitors: A systematic review and meta-analysis. Front. Nutr., 9.","DOI":"10.3389\/fonc.2021.726257"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1080\/01635581.2022.2153879","article-title":"Sarcopenia as a Determinant of the Efficacy of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: A Meta-Analysis","volume":"75","author":"Ren","year":"2023","journal-title":"Nutr. Cancer"}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/8\/1520\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T08:38:13Z","timestamp":1786091893000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/8\/1520"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,7]]},"references-count":28,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["medicina62081520"],"URL":"https:\/\/doi.org\/10.3390\/medicina62081520","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,7]]}}}